clofibric acid and fluorobenzenes

clofibric acid has been researched along with fluorobenzenes in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Doggrell, SA	1
Gadarla, M; Kearns, AK; Thompson, PD	1
Lupattelli, G; Mannarino, E; Roscini, AR; Siepi, D	1

Reviews

1 review(s) available for clofibric acid and fluorobenzenes

Article	Year
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints. Reviews on recent clinical trials, 2006, Volume: 1, Issue:2 Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2006

Article

Year

Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.

Reviews on recent clinical trials, 2006, Volume: 1, Issue:2

Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides

2006

Other Studies

2 other study(ies) available for clofibric acid and fluorobenzenes

Article	Year
Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. The American journal of cardiology, 2008, Jun-15, Volume: 101, Issue:12 Topics: Administration, Oral; Anticholesteremic Agents; Azetidines; Biological Products; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Dietary Supplements; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides	2008
Case report. Hyperlipoproteinaemia(a): which is the optimal therapy? A case report. Journal of clinical pharmacy and therapeutics, 2010, Volume: 35, Issue:5 Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type I; Male; Middle Aged; Myocardial Infarction; Niacin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2010

Article

Year

Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins.

The American journal of cardiology, 2008, Jun-15, Volume: 101, Issue:12

Topics: Administration, Oral; Anticholesteremic Agents; Azetidines; Biological Products; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Dietary Supplements; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides

2008

Case report. Hyperlipoproteinaemia(a): which is the optimal therapy? A case report.

Journal of clinical pharmacy and therapeutics, 2010, Volume: 35, Issue:5

Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type I; Male; Middle Aged; Myocardial Infarction; Niacin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides

2010